Abdalla EK et al. Improving resectability of hepatic colorectal metastases: Expert consensus statement. Ann Surg Oncol 2006;13(10):1271-80. Abstract
Abrams TA et al. Patterns of chemotherapy (CT) use in a US-wide population-based cohort of patients (pts) with metastatic colorectal cancer (mCRC). Proc ASCO 2012;Abstract 3537.
Arnold D et al. Bevacizumab (BEV) plus chemotherapy (CT) continued beyond first progression in patients with metastatic colorectal cancer (mCRC) previously treated with BEV plus CT: Results of a randomized phase III intergroup study (TML study). Proc ASCO 2012;Abstract CRA3503.
Donadon M et al. New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res 2007;1(1):20-7. Abstract
Fernandez FG et al. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240(3):438-47. Abstract
Grothey A et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013;381(9863):303-12. Abstract
Grothey A et al. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: Results from a large observational cohort study (BRiTE). J Clin Oncol 2008;26(33):5326-34. Abstract
Lacouture ME et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28(8):1351-7. Abstract
McCahill LE et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: Definitive analysis of NSABP trial C-10. J Clin Oncol 2012;30(26):3223-8. Abstract
McLoughlin JM et al. Resection of colorectal liver metastases: Current perspectives. Cancer Control 2006;13(1):32-41. Abstract
Meyerhardt JA et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: Findings from CALGB 89803. J Clin Oncol 2006;24(22):3535-41. Abstract
Nordlinger B et al. EORTC liver metastases intergroup randomized phase III study 40983: Long-term survival results. Proc ASCO 2012;Abstract 3508.
Nordlinger B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): A randomised controlled trial. Lancet 2008;371(9617):1007-16. Abstract
Pawlik TM et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg 2005;241(5):715-24. Abstract
Poultsides GA et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27(20):3379-84. Abstract
Van Cutsem E et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012;30(28):3499-506. Abstract
Zhu Y et al. Assessment of clinical benefit and quality of life in patients undergoing cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for management of peritoneal metastases. J Gastrointest Oncol 2013;4(1):62-71. Abstract